Drug Profile
Enzastaurin - Aytu BioPharma/ Denovo Biopharma
Alternative Names: AR-101 - Aytu BioPharma; DB 102; Enzastaurin hydrochloride; Kinenza; LY-317615Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Aytu BioPharma; Denovo Biopharma; Eli Lilly and Company
- Class Antineoplastics; Indoles; Piperidines; Pyridines; Pyrrolidinones; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Protein kinase C beta inhibitors; Protein-serine-threonine kinase inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diffuse large B cell lymphoma; Ehlers-Danlos syndrome; Glioblastoma
- Preclinical Connective tissue disorders
- Discontinued Brain cancer; Breast cancer; Cancer; Colorectal cancer; Follicular lymphoma; Lung cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia
Most Recent Events
- 14 Oct 2022 Aytu Biopharma suspends the phase III PREVEnt trial in Ehlers Danlos Syndrome (Adjunctive treatment, Prevention, In adults) in France, Netherlands, Sweden (PO, Tablet), due to indefinite hold by the company (NCT05463679) (EudraCT2021-006574-23)
- 12 Jul 2022 Denovo Biopharma completes the phase III ENGINE trial for Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in China and USA (PO) (NCT03263026)
- 31 May 2022 Phase-III clinical trials in Ehlers-Danlos syndrome (Adjunctive treatment, Prevention, In adults) in France, Netherlands, Sweden (PO) (EudraCT2021-006574-23)